Press Releases

Welcome to the Investing News Network's press release section, where you can stay informed with past and present announcements from our clients. Explore the latest stock news from mining, technology and life science companies and gain an investing edge by staying up to date with today's press releases.
Filters
Clear All Filters
Filter ✕

Date Range

Sector

BriaCell Therapeutics (BCT:CC)

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

biotech investing
Lexaria Bioscience (LEXX)

Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

biotech investing
BriaCell Therapeutics (BCT:CC)

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 

biotech investing
Lexaria Bioscience (LEXX)

Lexaria Celebrates its 70th Patent Award

biotech investing
BriaCell Therapeutics (BCT:CC)

BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer

biotech investing
Lexaria Bioscience (LEXX)

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

biotech investing
Lexaria Bioscience (LEXX)

Lexaria Announces Results From Animal Study GLP-1-A26-1

biotech investing
Lexaria Bioscience (LEXX)

Lexaria Announces Results from Animal Study GLP-1-A26-1

biotech investing
Lexaria Bioscience (LEXX)

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

biotech investing
BriaCell Therapeutics (BCT:CC)

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

pharmaceutical investing
BriaCell Therapeutics (BCT:CC)

BriaCell’s Bria-ABC Joins Roster of US-Enrolled Breast Cancer Trials

biotech investing
Lexaria Bioscience (LEXX)

Lexaria Updates Financial Position

biotech investing
BriaCell Therapeutics (BCT:CC)

Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

pharmaceutical investing
Lexaria Bioscience (LEXX)

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

biotech investing
Lexaria Bioscience (LEXX)

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

biotech investing
BriaCell Therapeutics (BCT:CC)

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

pharmaceutical investing
Lexaria Bioscience (LEXX)

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

biotech investing
BriaCell Therapeutics (BCT:CC)

BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation

biotech investing
Lexaria Bioscience (LEXX)

Lexaria Receives USD$2.6 Million Tax Rebate Payment

biotech investing
Lexaria Bioscience (LEXX)

DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

biotech investing

Latest News

More News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES